Phase 1 Trials of Gatralimab, a Next-Generation Humanized Anti-CD52 Monoclonal Antibody, in Participants with Progressive Multiple Sclerosis
Authors
- Frank Wagner
- Christian Geier (ORCID: https://orcid.org/0000-0001-5281-8187)
- M POSCH (ORCID: https://orcid.org/0009-0002-7315-9752)
- Philippe Truffinet (ORCID: https://orcid.org/0000-0002-5895-9981)
- Fredrik N. Albach (ORCID: https://orcid.org/0000-0002-2697-9080)
- Christian Keicher (ORCID: https://orcid.org/0000-0002-7552-4082)
- Annaig Le-Halpere (ORCID: https://orcid.org/0000-0002-9937-9916)
- Levent Akyüz (ORCID: https://orcid.org/0000-0003-1093-8505)
- Gerald Grütz (ORCID: https://orcid.org/0000-0003-4003-8639)
- Xiaodong Luo (ORCID: https://orcid.org/0000-0002-8214-9874)
- Stephan Schreiber (ORCID: https://orcid.org/0000-0003-4251-6067)
Institutions
- Sanofi (France) (FR)
- Menninger Clinic (US)
- Sanofi (United States) (US)
- Berlin-Brandenburger Centrum für Regenerative Therapien (DE)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Neurology and Therapy
- Published
- 2024-09-09
- DOI
- https://doi.org/10.1007/s40120-024-00659-w
- Citations
- 1
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 0.40
Funders
- Sanofi